VivoSeq
Other

Antipsychotics

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Antipsychotics is an early-stage landscape with 0 programs across 4 companies. The most active players are Johnson & Johnson, Otsuka, Merz Pharmaceuticals GmbH.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalOtsuka logo

Otsuka

0 programs

PreclinicalM

Merz Pharmaceuticals GmbH

0 programs

PreclinicalS

Solvay Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

32

clinical trials

Completed21 · 66%
Unknown status5 · 16%
Recruiting3 · 9%
Terminated2 · 6%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

32 trials

Effects of Antipsychotics on Brain Insulin Action in Females
Recruiting·CCentre for Addiction and Mental Health·N/A·NCT06251635·15 enrolled
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
Recruiting·GGuangdong Provincial People's Hospital·N/A·NCT07025590·106 enrolled
Developmental Effects of Antenatal Exposure to Antipsychotics
Recruiting·IIcahn School of Medicine at Mount Sinai·N/A·NCT06049953·74 enrolled
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
Not yet recruiting·CCentre for Addiction and Mental Health·Phase 4·NCT07109245·35 enrolled
Antipsychotics and Risk of Hyperglycemic Emergencies
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES·N/A·NCT02582736·725,489 enrolled
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
Completed·TTechnical University of Munich·Phase 4·NCT02307396·21 enrolled
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Completed·Otsuka logoOtsuka·Phase 3·NCT01432444·493 enrolled
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
Completed·CCentre for Addiction and Mental Health·Phase 4·NCT02640300·33 enrolled
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
Completed·UUniversity of Bergen·Phase 4·NCT00932529·226 enrolled
Metabolic Effects of Antipsychotics in Children
Completed·WWashington University School of Medicine·Phase 4·NCT00205699·144 enrolled
A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 4·NCT01682161·154 enrolled
The Effect of Hawthorn on Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics
Completed·CCalo Psychiatric Center·N/A·NCT03663465·135 enrolled
Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics
Completed·IInstituto Nacional de Psiquiatría Dr. Ramón de la Fuente·Phase 4·NCT01811160·50 enrolled
Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile
Completed·IInstitute of Mental Health, Singapore·Phase 4·NCT02949752·67 enrolled
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
Completed·JJohns Hopkins University·Phase 4·NCT00806234·127 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)